Cargando…
sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively kills tumor cells and augments chemotherapeutics in vivo. Here, we developed sTRAIL-iRGD, a recombinant protein consisting of sTRAIL fused to CRGDKGPDC, a C-terminal end binding peptide with an integrin-binding arginine-glyc...
Autores principales: | Huang, Ying, Li, Xihan, Sha, Huizi, Zhang, Lianru, Bian, Xinyu, Han, Xiao, Liu, Baorui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428854/ https://www.ncbi.nlm.nih.gov/pubmed/28373646 http://dx.doi.org/10.1038/s41598-017-00688-6 |
Ejemplares similares
-
iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer
por: Ding, Naiqing, et al.
Publicado: (2019) -
Anti-EGFR-iRGD recombinant protein conjugated silk fibroin nanoparticles for enhanced tumor targeting and antitumor efficiency
por: Bian, Xinyu, et al.
Publicado: (2016) -
Coupling Gd-DTPA with a bispecific, recombinant protein anti-EGFR-iRGD complex improves tumor targeting in MRI
por: XIN, XIAOYAN, et al.
Publicado: (2016) -
iRGD: A Promising Peptide for Cancer Imaging and a Potential Therapeutic Agent for Various Cancers
por: Zuo, Houdong
Publicado: (2019) -
Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation
por: Zhou, Shujuan, et al.
Publicado: (2021)